|
|
Article: Biocon Limited Presents Human Clinical Data on IN-105 (Oral Insulin) at the EASD Meeting in Rome.
- Article from:
- Business Wire
- Article date:
- September 8, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The Results Indicate that IN-105 is Safe and Well Tolerated by Type 2 Diabetic Patients and is able to Significantly Drop 2-Hour Post Prandial Glucose in a Dose-Related Manner
BANGALORE, India -- Biocon Limited, India's premier biotechnology company, announced the results of an ascending dose study with their oral insulin drug (IN-105) at the European Association for the Study of Diabetes (EASD) meeting in Rome on September 8, 2008. The study involved dosing Type 2 diabetes subjects with single doses of 0 mg (placebo), 10 mg, 15 mg, 20 mg and 30 mg tablets of IN-105 in 5 separate periods before a mixed 600 kcal breakfast. The outcome measurements were the safety ...